Payment overview · 2025
General Payments
$185.17
3 reported records · 3 companies
Healthcare provider profile · identity verified
James N Luckett, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FT LAUDERDALE, FL · NPI 1114938495
Verified facts
What the public records show
CMS Open Payments records show James N Luckett, MD received $185.17 in general payments during 2025 across 3 reported records.
EMD Serono, Inc. accounted for 75.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Serostim.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Serostim as an associated drug or biological on 153 records involving 74 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Serostim by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $139.70 | 75.4% | 1 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $33.13 | 17.9% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $12.34 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $185.17 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Serostim Normalized: serostim |
Drug | EMD Serono, Inc. | $139.70 | 1 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $33.13 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $33.13 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $12.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Serostim serostim |
2025 | Serostim | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Serostim open payments reported associated product |
CMS Open Payments — General Payments 153 supporting records · 74 recipient NPIs · example record 1236871463 |
Serostim · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 512 | 49 |
| Gabapentin | Gabapentin | 371 | 66 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 279 | 37 |
| Morphine Sulfate Er | Morphine Sulfate | 244 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 63 |
| Alprazolam | Alprazolam | 230 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 193 | 42 |
| Oxycontin | Oxycodone Hcl | 173 | 17 |
| Meloxicam | Meloxicam | 163 | 33 |
| Montelukast Sodium | Montelukast Sodium | 154 | 41 |
| Celecoxib | Celecoxib | 114 | 40 |
| Tivicay | Dolutegravir Sodium | 108 | 13 |
| Descovy | Emtricitabine/Tenofov Alafenam | 102 | 13 |
| Bupropion Xl | Bupropion Hcl | 95 | 26 |
| Valacyclovir | Valacyclovir Hcl | 87 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 84 | 16 |
| Trazodone Hcl | Trazodone Hcl | 82 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 80 | 16 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 80 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 16 |
| Metformin Hcl | Metformin Hcl | 76 | 16 |
| Dovato | Dolutegravir Sodium/Lamivudine | 72 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 70 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 16 |
| Lisinopril | Lisinopril | 65 | 16 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 63 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 62 | 12 |
| Naloxone Hcl | Naloxone Hcl | 61 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 15 |
| Pregabalin | Pregabalin | 60 | 12 |
| Testosterone | Testosterone | 59 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | suppressed |
| Finasteride | Finasteride | 54 | 13 |
| Omeprazole | Omeprazole | 54 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | suppressed |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Lorazepam | Lorazepam | 50 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | suppressed |
| Methylprednisolone | Methylprednisolone | 48 | 27 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 45 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 43 | suppressed |
| Tadalafil | Tadalafil | 40 | suppressed |
| Movantik | Naloxegol Oxalate | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 15 |
| Juluca | Dolutegravir/Rilpivirine | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Serostim | Somatropin | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Prednisone | Prednisone | 29 | 16 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 16 |
| Losartan Potassium | Losartan Potassium | 23 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 23 | suppressed |
| Xtampza Er | Oxycodone Myristate | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Entecavir | Entecavir | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Dronabinol | Dronabinol | 17 | suppressed |
| Nevirapine Er | Nevirapine | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Lamivudine | Lamivudine | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Cymbalta | Duloxetine Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Narcan | Naloxone Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $185.17 · 3 records | EMD Serono, Inc. | EGRIFTA, Serostim, TMS NeuroHealth Centers Inc., TROGARZO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Serostim play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with EMD Serono, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error